KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Operating Expenses (2017 - 2025)

Historic Operating Expenses for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to $822.8 million.

  • Biomarin Pharmaceutical's Operating Expenses rose 3022.54% to $822.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year increase of 315.4%. This contributed to the annual value of $2.4 billion for FY2024, which is 610.04% up from last year.
  • As of Q3 2025, Biomarin Pharmaceutical's Operating Expenses stood at $822.8 million, which was up 3022.54% from $548.5 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Operating Expenses registered a high of $822.8 million during Q3 2025, and its lowest value of $382.0 million during Q1 2022.
  • Over the past 5 years, Biomarin Pharmaceutical's median Operating Expenses value was $534.0 million (recorded in 2023), while the average stood at $545.2 million.
  • In the last 5 years, Biomarin Pharmaceutical's Operating Expenses tumbled by 1711.97% in 2022 and then soared by 3978.17% in 2023.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's Operating Expenses stood at $515.7 million in 2021, then grew by 6.77% to $550.6 million in 2022, then increased by 12.4% to $618.9 million in 2023, then decreased by 5.34% to $585.9 million in 2024, then soared by 40.44% to $822.8 million in 2025.
  • Its Operating Expenses was $822.8 million in Q3 2025, compared to $548.5 million in Q2 2025 and $521.3 million in Q1 2025.